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ABSTRACT

Compositions containing PBN, or active derivatives
thereof, in a suitable pharmaceutical carrier for adminis
tration to a patient, are disclosed for treating or prevent

ing gastric ulceration caused by ingestion of non-steroi
dal anti-in?ammatories. Based on animal studies, the
dosage is in the range of 3 to 300 mg/kg and is adminis

tered prior to, simultaneously, or shortly after ingestion
of the NSAID compound(s). In the preferred embodi
ment, the range is between 10 and 30 mg/kg, depending
on the dosage unit required to protect the mucosa. The
preferred method of administration is orally, alone or in
combination with the non-steroidal anti-in?ammatory.
It is believed that the PBN is also useful alone for treat

ment or prevention of ulcers, aspects of diarrhea, gastri
tis, esophagitis, ileitis, and as an analgesic.

16 Claims, 2 Drawing Sheets
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been obtained that ischemia may cause conjugated di
enes and malondialdehyde to accumulate in the tissue.
Even so, it remains to be conclusively shown that free

PHENYLBUTYL NITRONE COMPOSITIONS AND
METHODS FOR PREVENTION OF GASTRIC
ULCERATION

radical damage to unsaturated acyl chains in phospho
lipids, to protein, or to nucleic acids constitutes an im

portant role in the ischemic necrosis. At present, the
evidence is relatively strong for an involvement of free
radical mechanisms in vascular injury, and in damage
affecting nerve and glial cells.
Although no drugs are currently approved for clini
cal use in treating tissue damage due to ischemia, sev
eral compounds have been proposed as potentially
being effective. Mannitol, an oxygen scavenger, has

The United States Government has certain rights in
this invention by virtue of grants from the National
Institutes of Health.

BACKGROUND OF THE INVENTION
This is a continuation-in-part of US. Ser. No.

07/422,651 entitled “Phenyl Butyl Nitrone Composi
tions for Treatment of Oxidative Tissue Damage” ?led
Oct. 17, 1989 by John M. Carney and Robert A. Floyd.
This is generally in the area of compositions and

been added to reperfusion media to limit damage to

organs for transplantation. Superoxide dismutase

methods for use thereof for the treatment and preven

(SOD) has been suggested as a means for limiting in

tion of gastrointestinal ulceration resulting from the use
vivo oxidative damage. The most promising com
of nonsteroidal anti-inflammatory compounds, wherein
pounds that interfere with peroxidation generation are
the active compounds are phenyl butylnitrone (PBN) or
the lazaroides, modi?ed prednisones, described by J. M.
20
derivatives thereof.
McCall, Acta Anesthesia Belgica, First Antwerp Int.
Gastric ulceration is among the most important of
Trauma
Symp., which have been reported to be effica
adverse reactions from aspirin and nonsteroidal anti-in
cious if given during or after ischemia. White and Aust
?ammatory drugs (NSAIDS). The currently accepted
and co-workers, Adv. Free Radical Biol. Med.l,l-l7
explanation for NSAID-induced gastric ulceration is

that NSAIDS inhibit synthesis of cytoprotective prosta

25

(1985), and Babbs, Resuscitation 13, 165-173 (1986),

glandins, as reviewed by Whittle, B. R., and J. R. Vane.

have demonstrated that iron chelators protect animals

Arch. Toxicol. Suppl 7:315-322 (1984). This hypothesis
is supported by the demonstration that exogenous pros
taglandins protect from NSAID-relatecl gastric ulcers

from ischemia/reperfusion injury.

by Graham, D. Y., et a1. Lancet 2:1277-1280 (1988), but
challenged by recent studies showing that NSAIDS can

It is therefore an object of the present invention to
provide composition and methods for use thereof which
are useful in preventing or treating gastric ulcers result
ing from the use of non-steroidal anti-inflammatory

inhibit gastric prostaglandin production without caus

compounds.

ing ulceration, as reported by Rainsford, K. D., et al.

Scand. J. Gastroenterol. 19 (Suppl 101):_35-68 (1984);
Ligumsky, M., et a1. Gastroenterology 84:756-761
(1985); and Rainsford, K. D., “Relationship between
drug absorption, inhibition of cyclo-oxygenase and
lipoxygenase pathways and the development of gastric
mucosal damage of non-steroidal anti-in?ammatory

It is a further object of the present invention to pro
vide compositions and methods for use thereof which
are useful in preventing or treating pain and fever in
vivo resulting from infection and in?ammation.

SUMMARY OF THE INVENTION

Compositions containing PBN, or active derivatives

drugs in rats and pigs”. In Advances in Prostaglandins, 40 thereof, in a suitable pharmaceutical carrier for adminis
Leukotrienes and Lipoxins. M. J. Bailey, editor. Plenum
tration to a patient, are disclosed for treating or prevent
Press, New York, 639-653 (1985).. Thus, the cause of
ing
gastric ulceration caused by ingestion of non-steroi
NSAID-induced gastric ulceration remains controver
dal
anti-inflammatories. The compositions have the
sial, as reviewed by Rainsford, K. D. Toxicologic

Pathol. 16:251-259 (1988).

following general formula:

Free radicals have been postulated to be mediators of

tissue injury including that brought on by ischemical

H

reperfusion damage. Important production sites of the
oxygen free radicals Superoxide (02-) and hydroxyl
(OH) radicals are the mitochondrial respiratory chain

X

0'

\
/
C=N +
/
\

Y

and the reaction sequences catalyzed by cyclooxyge
nase and lipoxygenase. However, radicals are also

formed during autoxidation of many compounds (e.g.,

wherein:
X is phenyl or

catecholamines). Ischemic events in tissue causes a

spurt of free-radical formation. This may be due to

(OR)n

oxidation of polyenoic free fatty acids, release and reup
take of catecholamines, and oxidation of xanthine and

hypoxanthine by xanthine oxidase. Although all these
events occur during recirculation, when the 0; supply
is restored after ischemia, they represent metabolic
cascades triggered by agonistreceptor interactions, en
ergy failure, and/or calcium in?ux during the insult.
Although free radical formation is a likely cause of
ischemic damage, it has been dif?cult to directly dem
onstrate that such formation occurs and/or that it is 65

suf?ciently pronounced to overwhelm the antioxidative
defense of the tissue, Curran, et al., Mol. Cell. Biol. 5,
167-172 (1985). In recent years, however, evidence has

wherein R is H,

.

ll
Z—C-, or Z; or -CH=N

Y

and n is a whole integer from 1 to 5; or

5,036,097
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nized as uncouplers of mitochondrial oxidative phos
phorylation, and aspirin decreases mucosal adenosine

triphosphate (ATP) and phosphocreatine (PC) in iso
lated perfused gastric mucosa. Thus, aspirin and
. NSAIDS might be expected to produce changes in the
energy state of gastric mucosa similar to those caused

by ischemia, when ATP is depleted and then degraded

Y is a tert-butyl group that can be hydroxylated or
acetylated on one or more positions; phenyl; or

to hypoxanthine, as discussed by McCord, J. M. N.
l0

OW

wherein W is

Engl. J, Med. 312:l58—l63 (1985). Xanthine oxidase
mediated ischemia-reperfusion injury of the stomach
has recently been reported as a cause of stress ulceration

in hemorrhagic shock, as reported by Itoh, M., and P.
H. Guth. Gastroenterology 88:1162-1167 (1985); Perry,
M. A., et a1. Gastroenterology 90:362-367 (1986); and
15 Smith, S. M., Gastroenterology 92:950—-956 (1987). If
aspirin and NSAIDS impair mitochondrial energy me
tabolism, the subsequent breakdown of high energy
purines to xanthine might also stimulate xanthine oxi
dase-mediated
oxidant injury in gastric mucosa, result
20
ing in ulceration.
It has now been discovered that, further to the meth

ods using PBN for the treatment and prevention of
25

or Z; and
‘Z is a C1 to C5 straight or branched alkyl group.
Based on animal studies, the dosage is in the range of

ischemic damage, including by decreasing or prevent
ing ATP depletion, described and claimed in US. Ser.
No. 07/422,651 filed Oct. 17, I989, PBN, and deriva
tives thereof having spin-trapping activity, are useful in
preventing or treating gastric ulceration resulting from

ingestion of non-steroidal anti-inflammatories. As used
3 to 300 mg/kg and is administered prior to, simulta
neously, or shortly after ingestion of the NSAID com 30 herein, a free radical scavenger or spin-trap reagent is a ‘
molecule that will form a stable complex with a free
pound(s). In the preferred embodiment, the range is
radical. A free radical carbon trap is a molecule in
between 10 and 30 mg/kg, depending on the dosage
which
the free radical is localized on a carbon atom or
unit required to protect the mucosa. The preferred
a nitrogen atom. As a result of this chemical bond for
method of administration is orally, alone or in combina
tion with the non-steroidal anti-in?ammatory. It is be 35 mation, the free radical is no longer damaging to the
cell.
lieved that the PBN is also useful alone for treatment or

prevention of ulcers, aspects of diarrhea, gastritis,

a-phenyl t-butyl nitrone (PBN), and derivatives

esophagitis, ileitis, and possibly pain and fever in a man
ner analogous to analgesics such as aspirin and acetami

thereof, in a pharmaceutical ‘vehicle suitable for admin
istration to a patient, preferably by oral administration,
are useful in preventing or reversing gastric ulceration
caused by the use of ‘non-steroidal anti-in?ammatories
(NSAID). PBN has a number of advantages in the treat

nophen.

BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a comparison of the stomach from a pirox
ment of gastric ulceration, especially its complete lack
icam treated 'rat (right) to the stomach from a vehicle
of a measurable effect on normal or uninjured cells.
control treated rat (left). Piroxicam at 23 mg/kg caused 45 PBN is the preferred active compound at this time,
prominent ulceration along the ridges of gastric rugae.
although a number of derivatives are also useful, includ
FIG. 2 is a graph of % control ulceration from pirox
ing hydroxy derivatives, especially 2-, 3-or 4-hydroxy
icam versus the % ulceration in the presence of free
PBN and mono-, di- and trihydroxy tert-butyl nitrone;
radical scavengers. The sulthydryl scavenger dimethyl
esters, especially esters which release 2-, 3, or 4-hydrox

thiourea (DMTU, 500 mg/kg i.p.) was given 24 hours 50 yphenyl t-butyl nitrone such as the acetoxy derivative,
and 1 hour before piroxicam. The sulfhydryl scavenger
2-, 3-, or 4-carboxyphenyl t-butyl nitrone, such as the

N-acetylcysteine (300 mg/kg), the hydroquinone acet
aminophen (400 mg/kg) and the spin-trap phenylbutyl

nitrone (PBN, 30 mg/kg) were given orally 1 hour
before and along with piroxicam. The antioxidant butyl
ated hydroxytoluene (BHT, 25 mg/kg/day i.p. in corn
oil) was given for three days before and again 1 hour
before piroxicam. The % control ulceration is deter
mined by averaging the ratios of cm2 ulceration in con
trol stomachs from rats given piroxicam alone, and

multiplying><100. +P< 0.01 compared to piroxicam
alone.

55

ethyl derivative, or phenyl hydroxybutyl nitrone, such
as the acetoxy derivative; alkoxyl derivatives, especially
alkoxyl derivatives which release 2-, or 4-hydroxyphe
nyl t-butyl nitrone, such as the methyl derivative; and
acetamide derivatives, especially acetarnide derivatives
which release 2-, or 4 aminophenyl t-butyl nitrone, such
as the acetyl derivative; diphenyl nitrone (PPN) and the
analogous diphenyl nitrone derivatives. As used herein,
“PBN” refers to both a-phenyl t-butyl nitrone and de
rivatives thereof, unless otherwise stated. The active

agent in the compositions is N-tert-Butyl-a-phenylni

DETAILED DESCRIPTION OF THE
trone (PBN) or derivatives thereof that are spin trap
INVENTION
65 reagents and, in addition to chemical binding of free
radicals, may also act to prevent ATP depletion of cells.
Gastric parietal cells have abundant mitochondria to
. generate the energy required for hydrogen ion secre

tion. Salicylate and NSAIDS have long been recog

The general formula for PBN and useful derivatives
thereof is:

5,03 6,097
.

5

6

the conditions that result in the production of free radi
cals, the traps have little or no effect on normal cells.

H

X

O‘

\
/
C=N +
/
\

The bene?cial effects occur only in injured cells, and do

not require the presence of speci?c receptors, speci?c
enzymes, and/or speci?c cell types.
The PBN is preferably administered systemically,

Y

most preferably orally, since this is the most rapid and
ef?cient means for delivering the active compound to
the site of free radical generation. The PBN may be

wherein:
X is phenyl or

administered at once, or may be divided into a number

(0R)n

of smaller doses to be administered at varying intervals
of time. Other methods of administration can also be

used, including subcutaneous, intravenous, and intra-_

peritoneal administration. The pharmaceutical compo
15 sitions should provide a dosage of PBN relative to the

wherein R is H,

dosage of NSAID sufficient to protect the mucosa from
the effect of the NSAID. The concentration of active

compound in the drug composition will depend on
absorption, inactivation, and excretion rates of the drug ,
as well as other factors known to those skilled in the art.
The compositions are administered prior to, at the same

time as, or shortly after ingestion of the non-steroidal
anti-in?ammatories. The effective dosage may also be

and n is a whole integer from 1 to 5; or

determined based on that amount required to prevent or
25

Y is tert-butyl group that can be hydroxylated or

understood that for any particular subject, specific dos

acetylated on one or more positions; phenyl; or
OW

35

wherein W is

reverse predisposition of the cells to damage resulting
from depletion of ATP (as demonstrated by in vivo
NMR) and damage from free radical generation. It is to
be noted that dosage values will also vary with the
condition of the patient being treated. It is to be further
age regimens should be adjusted over time according to
the individual need and the professional judgment of the
person administering or supervising the administration
of the compositions, and that the concentration ranges
set forth herein are exemplary only and are not intended
to limit the scope or practice of the claimed composi
tion.
A preferred mode of administration of the active
compound is in a form for oral delivery. Oral composi
tions will generally include an inert diluent or an edible

carrier. Preferred pharmaceutical carriers for intrave
nous administration are saline or phosphate buffered

saline at physiological pH. Since PBN degrades at pH
45 less than approximately 3 to 4, it is preferred to adminis

ter the PBN at a pH of 4 or higher, or in combination

with food or a buffering agent. For oral delivery, the

PBN may be enclosed in capsules, compressed into
or Z; and
Z is a C1 to C5 straight or branched alkyl group.
The compositions can also contain other active
agents, such as buffering agents such as antacids or inert

tablets, microencapsulated, entrapped in liposomes, in

carriers such as lactose. Examples of commonly used

compatible binding agents, and/or adjuvant materials

NSAIDs include aspirin, acetaminophen, ibuprofen,
piroxicam, naphroxen, flufenamic and methanamic acid
and related nonsteroidal antiinflammatory compounds.
Examples demonstrate the utility of the compositions
in preventing or treating ulceration resulting from in
gestion of NSAIDs. Exemplary dosages of PBN ranged
from 3 to 300 mg/kg of body weight in animals. The
effective range of PBN in humans and other mammals is
expected to be between approximately _ l0 and 300

mg/kg, preferably between 10 and 30 mg/kg body
weight. The compositions can be effectively adminis
tered prior to, during or shortly after ingestion of

solution or suspension, alone or in combination with a

substrate immobilizing material such as starch or poorly
absorbable salts such as immodium. Pharmaceutically
can be included as part of the composition. The tablets

or, capsules may contain, for example, any of the fol
lowing ingredients, or compounds of a similar nature: a

binder such as microcrystalline cellulose, gum traga
canth or gelatin; an excipient such as starch or lactose,

a disintegrating agent such as alginic acid, Primogel ®,
or corn starch; a lubricant such as magnesium stearate
or Sterotes; a glidant such as colloidal silicon dioxide; a
sweetening agent such as sucrose or saccharin; or a

?avoring agent such as peppermint, methyl salicylate,
or orange flavoring. When the dosage unit form is a

NSAIDs, and prevent or decrease the extent of cellular 65 capsule, it can contain, in addition to material of the
above type, a liquid carrier such as a fatty oil. In addi

damage.

Since the trapping of endogenous free radicals is
speci?c for only ‘those cells that have been exposed to

tion, dosage unit forms can contain various other mate

rials which modify'the physical form of the dosage unit,

5,036,097
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for example, coatings of sugar, shellac, or other enteric

8

radius of greater curvature, washed with ice cold nor
mal saline, and spread along a ?at surface with lumens

agents.
exposed. Five punch biopsies from mucosal through
The present invention will be further understood
serosal surfaces are taken from each stomach using a 3
with reference to the following non-limiting examples
demonstrating methods for determining effectiveness of 5 mm diameter skin biopsy punch. Biopsies are taken over
ulcers in piroxicam treated stomachs and randomly
PBN administration for treatment or prevention and/or
reversal of damage from NSAIDS.
EXAMPLE 1: COMPARISON OF
PIROXICAM-INDUCED ULCER WITH
CONTROL.
The following materials and methods were used in

over gastric rugae (where ulcers occur) in vehicle con
trol stomachs. Biopsies from each stomach are com
bined, homogenized on ice in 1 ml of cold 1.15% KCl,
and mixed with 2 ml of TBA reagent (0.375% thiobarbi
turic acid and 15% trichloroacetic acid in 0.25 HCl, to

which 0.01% butylated hydroxytoluene is added just

prior to use). After incubation at 100° C. for 15 minutes,
the mixture is cooled and centrifuged at 1,500 g for 10
Animal Experiments.
15 min. The absorbance of the supernatant is measured at
Male Sprague-Dawley rats (Charles River, Wilming
532 nm, and results expressed as A532 per stomach.
ton, Mass.) weighing 300-325 g were housed individu
MEASUREMENT OF GLUTATHIONE IN
ally in wire bottomed cages to prevent ingestion of hair
GASTRIC MUCOSA.
and feces. Animals were maintained without food for 48
hours and without water for 24 hours prior to each 20
Gastric mucosal glutathione is measured in pirox
experiment. Piroxicam or aspirin and other NSAIDS
icam-and vehicle-treated rat stomachs. Four hours after
were suspended in a vehicle of 1% carboxymethylcellu
piroxicam or vehicle, stomachs are opened, washed
lose, 0.1% Tween 80 and 0.15 M HCl, and administered
with ice cold saline, and spread along a flat surface with
in a volume of 1 ml on the morning of study by oral
lumens exposed. The gastric mucosa is then removed by
gavage using an 18 gauge curved blunt needle (Popper 25 scraping with a surgical blade. The mucosa is homoge
and Sons, New Hyde Park, N.Y.). One ml of vehicle
nized on ice in 1 ml of 1.15% KCl. Two aliquots of 250
alone was administered for control experiments. HCl
pl are snap frozen in liquid nitrogen and stored at -—70°
was added to the vehicle to insure an acid environment
C. for later determination of total glutathione by the
in the stomach in all studies. Preliminary experiments
method of Anderson, M. E. Methods Enzymol
showed that 23 mg/kg piroxicam consistently produced 30 113:548-555 (1985) and protein by a modi?cation of the

examples 1 and 2.

ulceration, and this dose was used in all subsequent -

studies. Four hours after the administration of NSAID
or vehicle, rats were euthanized with sodium pentobar

Lowry method, described by Bennett, J. P. Techniques
Lipid Membrane Biochem. B408:1—22 (1982), using
bovine serum albumin as a standard. Results are ex

bital (100 mg/kg IP), and the surface area of ulceration
pressed as nmole/mg protein. To measure oxidized
per stomach was quantitated using morphometric tech 35 glutathione (GSSG), the remaining 500 pl is mixed with
niques. Stomachs were removed, the lumen was ex
an equal volume of N-ethylmaleimide (NEM) in water
posed by an incision along the radius of greater curva
(10
mM final concentration of NEM), snap frozen and
ture, and the stomach was washed in phosphate buff
stored at —70° C. After thawing for analysis, this mix
ered saline. The luminal surface was laid out on a flat

surface with gross folds removed by gentle distension. 40 ture is passed over a C-18 Sep-Pak column (Waters
Associates, Milford, Mass.) and washed with 1 ml phos
The percentage of surface involved with submucosal
phate buffer (pH 7.5). This technique for removing
hemorrhage was then determined by point counting, as
excess
NEM has been previously shown to result in
described by Weibel, E. R. Stereological Methods:
>90%
recovery of GSSG. GSSG is then assayed by
Practical Methods for Biological Morphometry. Aca
the
method
used above to determine total glutathione.
demic Press, New York 1980. This was done by tabula
tion of the percentage of points over ulcerations using a

point counting eyepiece graticle (16x16 points in a
square format). At the 12X magni?cation used on the

Wild dissecting microscope (Wild-Heerbrugg, Basel,

MEASUREMENT OF GASTRIC XANTHINE
OXIDASE ACTIVITY.

Xanthine dehydrogenase (XDH) and oxidase (X0)

Switzerland), the graticle covered a 1 cm2 area of the 50 activities are measured in whole stomach from pirox
icam-treated and vehicle-treated rats, using methods
surface. Four to live non-overlapping sampling sites
reported by Parks, et. al. Am. J. Pathol. 254 (Gastroint
were taken to fully cover the exposed surface. To deter
est Liver Physiol 17): G768-G774 (1988). The artifac
mine the total luminal surface area, the outline of the
tual conversion of XDH to X0 is minimized by quickly
outer boundary of the stomach was traced using a trans
parent acetate sheet, and the area was determined from 55 removing stomachs from rats that were anesthetized
with 50 mg/kg sodium pentobarbital and still breathing
planimetry. The surface area of ulcerated regions per
spontaneously. After gastrectomy, the rats are euth
stomach was then determined by multiplying the sur
anized by cutting the abdominal aorta. Stomachs are
face density of ulceration regions by the luminal surface
quickly rinsed in an ice cold homogenizing buffer con
area of the stomach.

cle-treated rat stomachs by measuring thiobarbituric

sisting of 50 mM potassium‘ phosphate buffer, pH 7.0,
containing 10 mM dithiothreitol (DTT), 1 mM phenyl
methylsulfonyl ?uoride (PMSF) and 0.1 mM EDTA.
The stomach is then immediately immersed in liquid
nitrogen and ground to a fine powder under liquid ni

acid (TBA) reactivity of gastric punch biopsies by the

65 trogen using a mortar and pestle. About 0.5 g of frozen

MEASUREMENT OF LIPID PEROXIDATION IN
STOMACHS.

Lipid peroxidation is studied in piroxicam-and vehi
method of Buege and Aust Buege, J. A., Aust, S. D.
Methods Enzymol 51:302-310 (1978). Four hours after
piroxicam or vehicle, stomachs are opened along the

powder is added to 5 ml of homogenizing buffer and
centrifuged 40,000 g for 30 min. The supernatant is
decanted and microfuged for an additional 10 min. Su
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after collection to prevent loss of activity.

I

The spectrophotometric assay used is based on pro
duction of uric acid at 295 nm (lambda295=1.l z
104M-lcm—l). To increase reaction rates activity was
measured at 30 rather than 25° C. One ml reaction mix

ene, pH 7.25. This suspension is frozen under liquid
nitrogen and stored at —70° CL until use. Microsomal

protein is determined by a modi?cation of the Lowry
method of Anderson, M. E. Methods Enzymol
113:548-555 (1985). The effect of 200 p.M piroxicam on

tures contained 500 pl sample, 50 p.M xanthine and 100

pM EDTA in 50 mM potassium phosphate buffer, pH

microsomal lipid peroxidation is studied by incubating 1
mg microsomal protein in 100 mM potassium phos

7.8. X0 is assayed in the absence in NAD+, while

XDH+XO activity is measured in the presence of 500
uM NAD+. Enzyme activities are reported as interna
tional units (1 umol of urate formed per min.). The
extent of XDH conversion (% X0) is calculated from

X0 activity divided by XDH+XO activity.
Studies of Mitochondrial Respiration.

10

The ?nal pellet is resuspended in storage buffer contain
ing 100 mM potassium phosphate, 20% glycerol, 1 mM
EDTA, 1 mM DTT and 20 uM butylated hydroxytolu

pematants are not stored but assayed less than 2 hours

phate, pH 7.25, on a shaking water bath at 37‘ CL for 90
min., with and without the addition of 2 mM NADPH
or 1 mM EDTA. Lipid peroxidation in the 1 ml reaction
mixture is measured by mixing with 2 ml TBA reagent
15

and assaying for thiobarbituric acid reactivity by the
method of Buege and Aust. Values are expressed as the
increase in absorbance at 532 nm (A532) per mg micro

Rat liver mitochondria are prepared using the
method of Lai and Clark Methods Enzymol 55:51-60
(1979). The livers are excised rapidly into ice cold isola
tion medium containing 0.25M sucrose, 10 mM tris(hy

somal protein and represent the mean of three repli
cates.

Statistical Analysis.

droxymethyl)aminomethane (Tris), 0.25% bovine

Differences in total luminal surface area in cmz, sur
face area of ulcerated regions per stomach and bio
chemical analyses between each treatment intervention
I placed in a Dounce homogenizer with 20 ml cold isola 25 and its corresponding untreated control group are com

serum albumin (fatty acid free), and 0.5 mM potassium
EDTA, pH 7.4. The tissue is minced and rinsed three
times in cold isolation medium. The minced tissue is

pared using the Mann-Whitney U Test, Dixon, W. J.,

tion medium, gently homogenized, and diluted with an
additional 10 ml of isolation medium. The homogenate
is centrifuged at 2,000 g for 3 min., and the resulting
supernatant recentrifuged at 12,500 g for 8 min. The
crude mitochondrial pellet is suspended in 0.12M man
nitol-0.03M sucrose medium containing 3% Ficoll,
gently layered onto 20 ml of 6% Ficoll (0.25M man
nitol-0.06M sucrose), and centrifuged at 11,500 g for 30

Massey, F, J ., Jr. Introduction to statistical methods, 4th

edition. (New York: McGraw Hill, 1983). The effect of
treatment interventions on NSAID-induced ulceration
are displayed graphically as % of control ulceration,

determined by summing the ratios of cm2 ulceration in
each treatment stomach to the mean cm2 ulceration of

respective untreated NSAID control stomachs, and
multiplying +100. In vitro studies are compared using

min. The resulting mitochondrial pellet is resuspended

the Student’s unpaired T-test, Dixon, W. .I., Massey, F.

in the isolation medium and recentrifuged for 10 min. at
12,500 g. The final pellet is brought to a concentration

J., Jr. Introduction to statistical methods, 4th edition.
(New York: McGraw Hill, 1983). Values are expressed
as mean-.LSEM. Signi?cance is assumed when P<0.05.

of 10 to 15 mg of mitochondrial protein per ml with

isolation medium. Mitochondrial protein is determined
by the Biuret reaction described by Gornall, A. G., et
al. Biol Chem 177:751-766 (1949), using bovine serum

EDTA at pH 7.4. State 4 respiratory rates are deter

Reagents and Pharmaceuticals.
Phenyl N-tert-butyl nitrone is obtained from Aldrich
Chemicals, Milwaukee, Wis. All other chemicals and
pharmaceuticals are from Sigma Chemical. Piroxicam
caused profound gastric ulceration. FIG. 1 shows that
piroxicam-induced ulcers usually occurred only on the
ridges of gastric rugae and spread linearly along these
ridges, without involvement of the remaining gastric

mined using both NADH-linked (2.5 mM malate+2

surface area. In the absence of an intervention, a mean

albumin as a standard. Mitochondrial respiration is mea

sured polarographically in a magnetically stirred cham
bet at 25° C., using a Clark microelectrode (Diamond
Electro-tech, Ann Arbor, Mich). The incubation me

dium contains the following (in mM): 5K+, 226 manni

45

tol, 75 sucrose, 5 Tris-phosphate, l0 Tris-Cl, and 0.05

rates are measured after stimulation with 1.5 mM ADP.
Respiratory control ratios are determined as the ratio of

of 0.215 cm2 ulceration was present in piroxicam-treated
control stomachs. However, the degree of ulceration in
this highly stress-dependent model was variable, rang
ing among experiments from 0.03 10.009 to

State 3 to State 4 respiration after incubation with 0, 50,

0706:0104 cmz. For this reason, each treatment inter

mM glutamate) and FADHz-lined (10 mM succinate)
substrates, with 5 mM KCl at pH 7.0. State 3 respiration

100 and 200 pM piroxicam.
Studies of Microsomal Lipid Peroxidation.

50

vention was compared to its own group of control rats
55

that were fasted simultaneously and treated with pirox
icam at the same time.

Microsomes are isolated from rat livers by modi?ca

EXAMPLE 2: SUPPRESSION OF
tion of the method of Fleisher and Kervina, Methods
PIROXICAM-INDUCED ULCERS BY FREE
Enzymol 31:7-41 (1974). Rats are euthanized by C02
RADICAL SCAVENGERS.
narcosis. The livers are excised rapidly into cold isola
Piroxicam was selected as a model NSAID because it
tion medium containing 0.1M sodium phosphate and 2
is highly ulcerogenic in rats and mice, yet is a relative
mM EDTA, pH 7.4. The tissue is minced and homoge
weak reversible inhibitor of prostaglandin synthesis.
nized in 3 ml isolation medium per gram of tissue using
The spin trap phenylbutyl nitrone (PBN) was used to
a Potter-Elvehjam homogenizer. The homogenate is
centrifuged at 17,800 g for 20 min., and the pellet dis 65 explore the role of free radicals and oxidative events
mediated by xanthine oxidase- and iron-mediated oxi
carded. The supernatant is recentrifuged at 100,000 g

for 60 min. The resulting pellet is. resuspended in isola
tion buffer and recentrifuged at 100,000 g for 40 min.

dant injury in the pathogenesis of piroxicam-induced

gastric ulcers. In each experiment, the surface area of

5,036,097

11

gastric ulceration produced by piroxicam in 15 treated
rats was compared to that in 15 rats of the same age and

size that were fasted simultaneously but which received

no intervention. Phenylbutyl nitrone (30 mg/kg) was
given orally in water 1 hour before piroxicam and also
added to vehicle when piroxicam was administered.
When intervention were given with piroxicam, the pH
of the ?nal mixture was adjusted if necessary to equal
that of piroxicam and vehicle alone.
To generalize the ?ndings relative to piroxicam to
other NSAIDS, the effect of PBN, administered as
above, can be compared with the effect on gastric ulcer

ation from aspirin (200 mg/kg), di?unisal (125 mg/kg),
naproxen (150 mg/kg) and ibuprofen (230 mg/kg).
Piroxicam-induced ulcers were markedly reduced in
rats treated with free radical scavengers, as shown in

12

PBN in concentrations of up to at least 100 pjmolar have
no cytotoxic effect.
In vivo toxicity tests have indicated the following.
Acute doses of PBN in doses up to 3 g/kg in rodents
have no adverse effects. An LD50 has yet to be deter
mined because of the lack of toxicity. Acute i.v. doses of

PBN ranging from 10 to 300 mg/kg body weight (in
jected within 60 seconds) have no acute toxic effects in
gerbils. Continuous i.v. administration of PBN at a dose
of 50 mg/kg/hr for a total of 48 hr has no adverse effect
on gerbils.
An estimate of the bioavailability of PBN demon
strates that it is widely available throughout the body
and is able to cross all of the barriers to distribution,

including the blood brain barrier (the brain shows 80%

of the plasma concentration). Limited pharmokinetic

FIG. 2, suggesting that generation of reactive oxygen
species is an important mechanism in the pathogensis of
piroxicam-induced ulcers. In ulcerations/unit area,

studies indicate that the plasma half-life in the rat is

piroxicam only produced 0229:0145 ulcerations/unit

compositions containing PBN and derivatives thereof,

area, and piroxicam plus PBN produced 0.077:0.l04
ulcerations/unit area, statistically signi?cant at
p<0.0052. In contrast, ascorbate, a reducing substance
that is well-recognized to facilitate iron-dependent gen
eration of reactive oxygen species, increased ulceration

and methods using the compositions for the treatment

by over 600% compared to control stomachs treated

with piroxicam alone (O.l94:0.039 cm2 ulceration in
ascorbate-treated stomachs vs 0031:0009 cm2 in

stomachs receiving piroxicam alone, P<0.00l). In sup
port of an oxidant mechanism as the pathogenesis of

ulcers from piroxicam, thiobarbituric acid reactivity
was signi?cantly increased in gastric biopsies from
piroxicam treated rats compared to rats treated with

vehicle alone (A532=0.lO4:0.0l0 for piroxicam vs 35
0.075:0.004 for vehicle treated stomachs, P<0.05).
Piroxicam also decreased total glutathione in gastric
mucosa (0.33:0.03 nmoles/mg protein) compared to
vehicle alone (0.042:0.07 nmoles/mg protein) and
increased the fraction of GSSG (8.9 :0.9 for piroxicam
vs 6.4 0.7% for vehicle), although these differences
failed to achieve statistical signi?cance.
Xanthine oxidase activity was readily identi?ed in
whole stomach. Piroxicam treated stomachs had
30.5:l.6 mU/g of total XHD+XO activity, of which
45 :3% was XO. Vehicle treated control stomachs had
31.6:2.45 mU/g X. Piroxicam increases the rate of

three to four hours.

Modi?cations and variations of the present invention,

or prevention of gastric ulceration resulting from inges
tion of non-steroidal anti-inflammatories, will be obvi
ous to those skilled in the art from the foregoing de

tailed description. Such modi?cations and variations are
intended to come within the scope of the following
claims.
We claim:
1. A method for in vivo treatment or prevention of

gastric ulceration from ingestion of non-steroidal anti

in?ammatories comprising:
administering to a patient in need of such treatment

a-phenyl t-butyl nitrone and derivatives thereof
having spin-trapping activity and preventing ATP
depletion in vivo in tissue having the formula;

wherein:
X is phenyl or
(OR)n

mitochondrial oxygen uptake in the absence of ADP '

(State 4) and that normal stimulation of respiration by
ADP (State 3) is lost in the presence of piroxicam. This 50
inhibition of respiratory control by piroxicam was dem
onstrated for both FADHg-linked and NADH-linked
substrates. However, piroxicam did not increase gener
ation of OZ-by mitochondrial respiration. Piroxicam had
no effect on NADPH-dependent microsomal lipid
peroxidation.

wherein R is H,
O

0

>

Aspirin (0972:0318 cmz), diflunisal (0597:0103
cmz), naproxen (0370:0056 cm2) and ibuprofen
(0644:0110 cmZ) also caused severe gastric ulcer-,
ation. In summary, ulceration from piroxicam was

and n is a whole integer from 1 to 5; or

markedly inhibited by the spin-trap PBN.
EXAMPLE 3: NON-TOXICITY OF PBN AND
BIOAVAILABILITY.

'

Previous studies on mutagenicity using standard tech 65

niques have demonstrated that PBN and analogs
thereof are not mutagenic. In addition, in vitro cytotox
icity tests using human lymphocytes have indicated that

Y is a tert-butyl group that can be hydroxylated or
acetylated on one or more positions; phenyl; or
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C=N+

\
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X

Y

wherein:
X is phenyl or

wherein W is
O

(OR)n

ff
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or Z; and
Z is a C1 to C5 straight or branched alkyl group; and
a pharmaceutically acceptable carrier for oral admin- 20

wherein R is H,
O

0

ll

/
Z—C—, or Z; or -'CH=N
\

istration to a patient, in a dosage effective to treat

or prevent gastric ulceration from ingestion of

,

Y

and n is a whole integer from 1 to 5; or

nonsteroidal antiinflammatory compounds.
, 2. The method of claim 1 wherein the phenyl butyl
nitrone derivatives are selected from the group consist 25

ing of hydroxy PBNs, PBN esters, acetoxy PBNs, alkyl
PBNs, alkoxyl PBNs, phenyl PBNs.
3. The method of claim 1 wherein the PBN derivative
is functionalized to release in vivo a compound selected
Y is a tert-butyl group that can be hydroxylated or
acetylated on one or more positions; phenyl; or

from the group consisting of 2-, 3-, and 4-hydroxyphe

nyl t-butyl nitrone; 2-, 3-, and 4-hydroxyphenyl t-butyl
nitrone; 2-, 3-, and 4-carboxyphenyl t-butyl nitrone; and
2-, 3-, and 4-aminophenyl t-butyl nitrone._

OW

4. The method of claim 1 comprising as the active 35

ingredient a-phenyl t-butyl nitrone.
5. The method of claim 1 wherein the PBN and deriv

atives thereof is in a pharmaceutical carrier delivering
an effective dosage to a patient to treat or prevent gas

wherein W is

tric ulceration from simultaneous ingestion of nonsteroi

dal antiinflammatory compounds.
6. The method of claim 1 wherein the PBN and deriv

atives thereof is in a pharmaceutical carrier delivering
an effective dosage to a patient to treat or prevent gas

tric ulceration from subsequent ingestion of non-steroi

dal anti-inflammatoriy compounds.

45
o

o

I!

7. The method of claim 6 wherein the non-steroidal
anti-in?ammatory is selected from the group consisting

of aspirin, acetaminophen, ibuprofen, piroxicam, na
proxen, flufenamic and methanamic acid and related 50

nonsteroidal antiinflammatory compounds.

a pharmaceutically acceptable carrier for oral admin
istration to a patient, wherein the a-phenyl t-butyl

8. The method of claim 1 wherein the PBN and deriv
atives thereof is provided in a dosage of between 3 and

300 mg PBN/kg body weight.
9. The method of claim 8 wherein the PBN and 55
derivaties thereof is provided in a dosage of between 10

and 30 mg/kg body weight.
10. The method of claim 1 wherein the PBN and
derivatives thereof is provided in combination with a
pharmaceutical carrier selected from the group consist

ing of microcapsules, liposomes, immobilizing sub
strates, salts that are poorly absorbed through the gas

trointestinal lining, oils, and buffering agents.
11. A composition for in vivo treatment or prevention

of gastric ulceration comprising:
a-phenyl t-butyl nitrone and derivatives thereof hav
ing spintrapping activity and preventing ATP de
pletion in vivo in tissue having the formula;

or Z; and
Z is a C1 to C5 straight or branched alkyl group; and

nitrone and derivatives thereof is in a dosage effec
tive to prevent or treat gastric ulceration by non

steroidal antiinflammatory compounds wherein the
PBN and derivatives thereof is in combination with
a non-steroidal anti-in?ammatory, said agents
being present in effective amounts.
12. The composition of claim 11 wherein the phenyl
butyl nitrone derivatives are selected from the group

consisting of hydroxy PBNs, PBN esters, acetoxy

PBNs, alkyl PBNs, alkoxyl PBNs, phenyl PBNs.
13. The composition of claim 2 wherein the PBN
65 derivative is functionalized to release in vivo a com

pound selected from the group consisting of 2-, 3-, and

4-hydroxyphenyl t-butyl nitrone; 2-, 3-, and 4-hydrox
yphenyl t-butyl nitrone; 2-, 3-, and 4-carboxyphenyl

15
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t-butyl nitrone; and 2-, 3-, and 4-aminophenyl t-butyl

injury from simultaneous ingestion of a non-steroidal

nitrone.
14. The composition of claim 11 comprising as the

16. The composition of claim 11 wherein the non
steroidal anti-in?ammatory is selected from the group

anti-in?ammatory compound.

active ingredient a-phenyl t-butyl nitrone.

consisting of aspirin, acetaminophen, ibuprofen, pirox

15. The composition of claim 11 wherein the PBN

'icam, naproxen, ?ufenamic and methanamic acid and

and derivatives thereof is in a pharmaceutical carrier .

related nonsteroidal antiinflammatory compounds.
*

delivering an effective dosage to a patient to prevent
1O
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